Hydroxychloroquine is neutral on incidental cataracts in patients with rheumatoid arthritis
Abstract To study whether hydroxychloroquine (HCQ) therapy increases the risks of cataracts in patients with rheumatoid arthritis (RA). In this retrospective cohort study, 2821 treatment-naive RA patients, collected from the Longitudinal Health Insurance Database, were enrolled from 2000 to 2012 and...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-04-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-023-32297-x |
| _version_ | 1827970410425090048 |
|---|---|
| author | Zhibo Zhang Xin Ma Yu-Hsun Wang Xiaofei Shi James Cheng-Chung Wei |
| author_facet | Zhibo Zhang Xin Ma Yu-Hsun Wang Xiaofei Shi James Cheng-Chung Wei |
| author_sort | Zhibo Zhang |
| collection | DOAJ |
| description | Abstract To study whether hydroxychloroquine (HCQ) therapy increases the risks of cataracts in patients with rheumatoid arthritis (RA). In this retrospective cohort study, 2821 treatment-naive RA patients, collected from the Longitudinal Health Insurance Database, were enrolled from 2000 to 2012 and followed up monthly until secondary cataracts were detected but no later than Dec 31, 2013. All participants were split into two groups according to the usage of HCQ in one year: the HCQ group (465 patients), with a usage duration higher than 90 days, and the non-HCQ group (465 patients), with a usage duration less than 30 days. The HCQ and non-HCQ groups were age-, sex-, complication- and drug combination-matched. There was no significant difference in survival rate between the two groups (p > 0.05). A multivariate logistic regression model was applied. Of all participants, 173 were diagnosed with secondary cataracts in both the HCQ and non-HCQ groups, with 28.8/1000 and 36.5/1000 person-years, respectively. After adjustments for other predictors, patients in the HCQ group had no increased (or decreased/equal) hazard of secondary cataract (hazard ratio (HR): 1.17; confidence interval (CI): 0.86–1.59; p > 0.05). HR analysis of HCQ usage duration, age, sex and corticosteroids showed that the CI of the adjusted HR was not statistically significant. This study showed that HCQ usage was not associated with the risk of cataracts in RA patients. |
| first_indexed | 2024-04-09T18:53:26Z |
| format | Article |
| id | doaj.art-0b89a5e219fe4424ba02dd414dc07216 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-09T18:53:26Z |
| publishDate | 2023-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-0b89a5e219fe4424ba02dd414dc072162023-04-09T11:17:14ZengNature PortfolioScientific Reports2045-23222023-04-011311810.1038/s41598-023-32297-xHydroxychloroquine is neutral on incidental cataracts in patients with rheumatoid arthritisZhibo Zhang0Xin Ma1Yu-Hsun Wang2Xiaofei Shi3James Cheng-Chung Wei4Department of Rheumatology and Immunology, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and TechnologyDepartment of Rheumatology and Immunology, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and TechnologyDepartment of Medical Research, Chung Shan Medical University HospitalDepartment of Rheumatology and Immunology, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and TechnologyDepartment of Allergy, Immunology and Rheumatology, Chung Shan Medical University HospitalAbstract To study whether hydroxychloroquine (HCQ) therapy increases the risks of cataracts in patients with rheumatoid arthritis (RA). In this retrospective cohort study, 2821 treatment-naive RA patients, collected from the Longitudinal Health Insurance Database, were enrolled from 2000 to 2012 and followed up monthly until secondary cataracts were detected but no later than Dec 31, 2013. All participants were split into two groups according to the usage of HCQ in one year: the HCQ group (465 patients), with a usage duration higher than 90 days, and the non-HCQ group (465 patients), with a usage duration less than 30 days. The HCQ and non-HCQ groups were age-, sex-, complication- and drug combination-matched. There was no significant difference in survival rate between the two groups (p > 0.05). A multivariate logistic regression model was applied. Of all participants, 173 were diagnosed with secondary cataracts in both the HCQ and non-HCQ groups, with 28.8/1000 and 36.5/1000 person-years, respectively. After adjustments for other predictors, patients in the HCQ group had no increased (or decreased/equal) hazard of secondary cataract (hazard ratio (HR): 1.17; confidence interval (CI): 0.86–1.59; p > 0.05). HR analysis of HCQ usage duration, age, sex and corticosteroids showed that the CI of the adjusted HR was not statistically significant. This study showed that HCQ usage was not associated with the risk of cataracts in RA patients.https://doi.org/10.1038/s41598-023-32297-x |
| spellingShingle | Zhibo Zhang Xin Ma Yu-Hsun Wang Xiaofei Shi James Cheng-Chung Wei Hydroxychloroquine is neutral on incidental cataracts in patients with rheumatoid arthritis Scientific Reports |
| title | Hydroxychloroquine is neutral on incidental cataracts in patients with rheumatoid arthritis |
| title_full | Hydroxychloroquine is neutral on incidental cataracts in patients with rheumatoid arthritis |
| title_fullStr | Hydroxychloroquine is neutral on incidental cataracts in patients with rheumatoid arthritis |
| title_full_unstemmed | Hydroxychloroquine is neutral on incidental cataracts in patients with rheumatoid arthritis |
| title_short | Hydroxychloroquine is neutral on incidental cataracts in patients with rheumatoid arthritis |
| title_sort | hydroxychloroquine is neutral on incidental cataracts in patients with rheumatoid arthritis |
| url | https://doi.org/10.1038/s41598-023-32297-x |
| work_keys_str_mv | AT zhibozhang hydroxychloroquineisneutralonincidentalcataractsinpatientswithrheumatoidarthritis AT xinma hydroxychloroquineisneutralonincidentalcataractsinpatientswithrheumatoidarthritis AT yuhsunwang hydroxychloroquineisneutralonincidentalcataractsinpatientswithrheumatoidarthritis AT xiaofeishi hydroxychloroquineisneutralonincidentalcataractsinpatientswithrheumatoidarthritis AT jameschengchungwei hydroxychloroquineisneutralonincidentalcataractsinpatientswithrheumatoidarthritis |